[HTML][HTML] Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
YH Kuo, SN Lu, YY Chen, KM Kee, YH Yen… - Frontiers in …, 2021 - frontiersin.org
Background Lenvatinib is approved for patients with advanced hepatocellular carcinoma
(HCC) due to its non-inferiority to sorafenib of overall survival (OR) in clinical trials. This …
(HCC) due to its non-inferiority to sorafenib of overall survival (OR) in clinical trials. This …
[HTML][HTML] Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
YH Kuo, SN Lu, YY Chen, KM Kee, YH Yen… - Frontiers in …, 2021 - ncbi.nlm.nih.gov
Background Lenvatinib is approved for patients with advanced hepatocellular carcinoma
(HCC) due to its non-inferiority to sorafenib of overall survival (OR) in clinical trials. This …
(HCC) due to its non-inferiority to sorafenib of overall survival (OR) in clinical trials. This …
Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
YH Kuo, SN Lu, YY Chen, KM Kee, YH Yen… - Frontiers in …, 2021 - pure.lib.cgu.edu.tw
Background: Lenvatinib is approved for patients with advanced hepatocellular carcinoma
(HCC) due to its non-inferiority to sorafenib of overall survival (OR) in clinical trials. This …
(HCC) due to its non-inferiority to sorafenib of overall survival (OR) in clinical trials. This …
Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
YH Kuo, SN Lu, YY Chen, KM Kee… - Frontiers in …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Lenvatinib is approved for patients with advanced hepatocellular carcinoma
(HCC) due to its non-inferiority to sorafenib of overall survival (OR) in clinical trials. This …
(HCC) due to its non-inferiority to sorafenib of overall survival (OR) in clinical trials. This …
Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
YH Kuo, SN Lu, YY Chen, KM Kee, YH Yen… - Frontiers in …, 2021 - pure.lib.cgu.edu.tw
Background: Lenvatinib is approved for patients with advanced hepatocellular carcinoma
(HCC) due to its non-inferiority to sorafenib of overall survival (OR) in clinical trials. This …
(HCC) due to its non-inferiority to sorafenib of overall survival (OR) in clinical trials. This …